GlassScriptPhysician profile
Xintong Li
NPI 1497118830
$1,708.66
in general payments reported to CMS, 2019-2025
19 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $70.96 · 2021: $360 · 2022: $182 · 2023: $625 · 2024: $354 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,096.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $255.23 | 2021-2025 | Istent Trabecular Micro-Bypass System Model Is3, Idosetr |
| Alcon Vision LLC | $203.45 | 2023 | Clareon |
| Rxsight INC | $203.22 | 2023-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Horizon Therapeutics Plc | $200.08 | 2022-2023 | Tepezza |
| Amgen INC. | $158.87 | 2024-2025 | Tepezza |
| Allergan, INC. | $151.54 | 2020-2021 | |
| Apellis Pharmaceuticals, INC. | $100.14 | 2024 | Syfovre |
| Novartis Pharmaceuticals Corporation | $94.86 | 2022-2023 | |
| Biotissue Holdings INC. | $74.06 | 2021-2024 | |
| Abbvie INC. | $62.08 | 2022-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $39.58 | 2020-2021 | |
| Oyster Point Pharma, INC. | $33.64 | 2024 | Tyrvaya |
| Harrow Eye, LLC | $33.62 | 2025 | Vevye |
| Dompe US, INC. | $18.41 | 2022 | |
| Eyevance Pharmaceuticals LLC | $17.93 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $17.04 | 2022 | |
| Bausch & Lomb Americas INC. | $15.84 | 2023 | Xiidra |
| Ocular Therapeutix, INC. | $14.80 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $14.27 | 2024 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xintong Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.